These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24807631)

  • 1. Clusterin expression in gastrointestinal neuroendocrine tumours is highly correlated with location and is helpful in determining the origin of liver metastases.
    Mourra N; Scriva A; Mansiaux Y; Gozlan S; Bennis M; Balaton A
    Histopathology; 2014 Nov; 65(5):642-50. PubMed ID: 24807631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clusterin expression in medullary thyroid carcinoma is inversely correlated with the presence of lymph node metastases.
    Mourra N; Bennis M; Boelle PY; Cochand-Priollet B; Lefevre M; Lepine C; Balaton A; Klijanienko J; Menegaux F; Tissier F
    Hum Pathol; 2017 Jun; 64():37-43. PubMed ID: 28411179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
    Yang Z; Klimstra DS; Hruban RH; Tang LH
    Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
    Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.
    Czeczok TW; Stashek KM; Maxwell JE; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):94-100. PubMed ID: 29420353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors.
    Li B; Li X; Mao R; Liu M; Fu L; Shi L; Zhao S; Fu M
    Endocr Pathol; 2021 Jun; 32(2):301-308. PubMed ID: 32869188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours.
    Stricker I; Tzivras D; Nambiar S; Wulf J; Liffers ST; Vogt M; Verdoodt B; Tannapfel A; Mirmohammadsadegh A
    Anticancer Res; 2012 Sep; 32(9):3699-706. PubMed ID: 22993308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
    Desouki MM; Lioyd J; Xu H; Cao D; Barner R; Zhao C
    Hum Pathol; 2013 Nov; 44(11):2536-41. PubMed ID: 24029704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clusterin is highly expressed in pancreatic endocrine tumours but not in solid pseudopapillary tumours.
    Mourra N; Couvelard A; Tiret E; Olschwang S; Flejou JF
    Histopathology; 2007 Feb; 50(3):331-7. PubMed ID: 17257128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours.
    Jernman J; Välimäki MJ; Louhimo J; Haglund C; Arola J
    Neuroendocrinology; 2012; 95(4):317-24. PubMed ID: 22327359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
    Bellizzi AM
    Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
    Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
    J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
    Niederle MB; Hackl M; Kaserer K; Niederle B
    Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma.
    Perry KD; Reynolds C; Rosen DG; Edgerton ME; T Albarracin C; Gilcrease MZ; Sahin AA; Abraham SC; Wu Y
    Histopathology; 2011 Oct; 59(4):619-30. PubMed ID: 22014043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
    Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
    Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary Carcinoids and Low-Grade Gastrointestinal Neuroendocrine Tumors Show Common MicroRNA Expression Profiles, Different from Adenocarcinomas and Small Cell Carcinomas.
    Yoshimoto T; Motoi N; Yamamoto N; Nagano H; Ushijima M; Matsuura M; Okumura S; Yamaguchi T; Fukayama M; Ishikawa Y
    Neuroendocrinology; 2018; 106(1):47-57. PubMed ID: 28208131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
    Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
    Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
    Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
    Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
    Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
    APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.